AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00570661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
Study NCT02152397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-led brief intervention (TBI)
Study NCT03964337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Radical prostatectomy as part of routine medical care.
Study NCT03071666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cobalamin
Description: Vitamin supplment tablet containing 50µg cobalamin
Study NCT01687673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
Study NCT01687673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib:
Description: 200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
Study NCT01431300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadofosveset
Description: Intravenous administration of the specified dosage of gadolinium contrast agent
Study NCT01431300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadofosveset
Description: Intravenous administration of the specified dosage of gadolinium contrast agent
Study NCT00445588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150mg Given orally once daily
Study NCT00445588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: 400mg Given orally twice daily
Study NCT00445588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02241889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Subject's own insulin pump will be used to manage blood glucose.
Study NCT02241889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop Artificial Pancreas Controller
Description: Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
Study NCT05747404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: - Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
Study NCT04082247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The education and training of early childhood educators and their intervention on children
Description: A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes.
Study NCT03706651 — intervention group
Intervention type: DEVICE
Intervention: Infants hospitalized in health facilities performing Tele-expertise
Study NCT04034953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Faecal Immunochemical Test
Description: Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
Study NCT04034953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Prostate-Specific Antigen Test
Description: PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
Study NCT04034953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mammogram
Description: Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
Study NCT01456975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve reimplantation using Valsalva prosthesis
Description: Aortic valve reimplantation (David procedure)using Valsalva prosthesis
Study NCT01356173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0349
Description: Oral escalating dose
Study NCT02982720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously.
Study NCT02054858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
Study NCT00904787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: capsule, dose escalation, taken orally, daily in 28 day cycles
Study NCT01295268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emu Oil
Description: Subjects will apply a specified amount of emu oil daily to area.
Study NCT01295268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert oil
Description: A specified amount of inert oil will be applied daily to area.
Study NCT01871103 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The dorsal homodigital island flap
Description: The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
Study NCT03483532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lit Control pH Up
Description: dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
Study NCT03886623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care oral care
Description: Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
Study NCT04597151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Attend diet education sessions
Study NCT00294281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Description: The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
Study NCT00814216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680
Study NCT00814216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for QAV680
Study NCT00814216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Study NCT02591771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
Study NCT00827931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid + Standard of Care
Description: Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
Study NCT00827931 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
Study NCT06046352 — intervention group
Intervention type: PROCEDURE
Intervention: Electrophysiological study (and ablation when appropriate)
Description: Electrophysiological study (and ablation when appropriate)
Study NCT01612845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic repair without platelet rich fibrin
Description: after the tendon is repaired, no additional procedures are performed and no PRF is administered
Study NCT01612845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF (vivostat ®) administration after rotator cuff repair
Description: 7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
Study NCT01905423 — intervention group
Intervention type: DRUG
Intervention: Albendazole (annual)
Description: Albendazole 400 mg pnce annually
Study NCT01905423 — intervention group
Intervention type: DRUG
Intervention: Diethylcarbamazine (annual)
Description: Diethylcarbamazine 6 mg/kg once annually
Study NCT02982720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sylatron
Description: Sylatron will be administered subcutaneously.
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
Study NCT03483532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: dry cocoa extract
Description: (Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
Study NCT01905423 — intervention group
Intervention type: DRUG
Intervention: Albendazole (semiannual)
Description: Albendazole 400 mg twice annually
Study NCT03071666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A tablet identical to the vitamin supplement but containing no vitamin B12
Study NCT01905423 — intervention group
Intervention type: DRUG
Intervention: Diethylcarbamazine (semiannual)
Description: Diethylcarbamazine 6 mg/kg twice annually
Study NCT01146860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNO 1016
Description: sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
Study NCT04425928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy based activity training programs
Description: Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
Study NCT01146860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily weight measurement and monitoring
Description: Monitor weight to avoid problems related to hypervolemia.
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Dietary education
Description: To improve diet and health
Study NCT03534648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 administered Day 7-14
Description: PF-06865571 administered Q12hr on Days 7-14
Study NCT03534648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 administered Day 1-14
Description: PF-06865571 administered Q12hr on Day 7-14
Study NCT03534648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 administered Day 1-14
Description: PF-05221304 administered Q12hr on Days 1-14
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused advanced directive program
Description: Education will be provided to increase awareness and encourage patients to have advanced directive.
Study NCT02085837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Countdown to fistula program
Description: To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
Study NCT01196130 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cancer Symptom Questionnaire
Description: 5 minute questionnaire(s) completed at each study visit.
Study NCT01196130 — intervention group
Intervention type: OTHER
Intervention: Biomarker Testing
Description: Blood draw at each study visit for biomarker and cytokine testing.
Study NCT01990300 — intervention group
Intervention type: DRUG
Intervention: Alogliptin/Pioglitazone
Description: Alogliptin/Pioglitazone combination tablets
Study NCT02552433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: protein intake assessment and optimisation
Study NCT01215708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: tamsulosin 0,4mg every night for 30 consecutive days
Study NCT04425928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy based exercise training programs
Description: Cawthorne-cooksey exercises were performed at vestibular rehabilitation
Study NCT04877210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
Study NCT04877210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
Study NCT04877210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
Study NCT00633256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: 50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
Study NCT00633256 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
Study NCT05710562 — intervention group
Intervention type: OTHER
Intervention: Name not applicable
Description: In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
Study NCT03534648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 administered Day 7-14
Description: PF-05221304 administered Q12hr Days 7-14
Study NCT01215708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: tamsulosin 0,4mg every night for 30 consecutive days
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
Study NCT02173600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-level Intensive dietary Counselling
Study NCT02173600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-level Intensive Dietary Counselling
Study NCT02095860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
Study NCT03464240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: glucose drink
Study NCT03464240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: control
Study NCT02987439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The intervention is pulmonary rehabilitation
Study NCT04280120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilisation
Description: Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.
Study NCT04280120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
Study NCT04280120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
Study NCT04280120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Faradic electrical stimulation
Description: Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
Study NCT04280120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Faradic electrical stimulation
Description: Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
Study NCT04280120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
Study NCT04280120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study NCT02247414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotrophin
Description: Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.